DouglasGrahamMDPhD

PubMed

• 534 citations
  TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer
  Rachel M. A. Linger, Amy K. Keating, H. Shelton Earp, Douglas K. Graham
  Advances in Cancer Research. 2008-01-01
• 20 citations
  Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.
  Miyoung Lee, Jamie A G Hamilton, Ganesh R Talekar, Anthony J Ross, Langston Michael
  Nature Communications. 2022-03-03
• 514 citations
  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
  Douglas K. Graham, Deborah DeRyckere, Kurtis D. Davies, H. Shelton Earp
  Nature Reviews. Cancer. 2014-12-01

Journal Articles

• Efficacy of a dual Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia  
  Lee Sherick A, Zhang W, Menachof K, Hill A, Rinella S, Stashko M, Jordan C, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, and DK Graham, Oncotarget, 1/1/2015
• The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer  
  Graham DK, DeRyckere D, Davies KD, and HS Earp, Nat Rev Cancer, 1/1/2014
• Epigenetic reprogramming to reverse chemoresistance in childhood acute lymphoblastic leukemia  
  Newton TP, Cummings CT, Graham DK, and KM Bernt, International Journal of Hematologic Oncology, 1/1/2014
• mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop  
  Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, and LE Heasley, Oncogenesis, 1/25/2013
• Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T cell acute lymphoblastic leukemia  
  Brandao L, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, DeRyckere D, and DK Graham, Blood Cancer J, 1/1/2013
• Mer receptor tyrosine kinase is a novel therapeutic target in melanoma  
  Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Alldredg..., J Clin Invest, 1/1/2013
• Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia  
  Liu J, Yang C, Simpson C, DeRyckere D, Van Deusen AV, Miley MJ, Kireev D, Nouis-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL..., ACS Med Chem Lett, 1/1/2012
• Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus  
  Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RMA, DeRyckere D, and DK Graham, PLoS ONE, 1/1/2012
• Inhibition of Mer and Axl receptor tyrosine kinases reduces astrocytoma cell growth and increases chemosensitivity  
  Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, and DK Graham, Mol Cancer Ther, 1/1/2010
• TYRO3 (TYRO3protein tyrosine kinase)  
  Jacobsen KM, Linger RMA, and DK Graham, Atlas Genet Cytogenet Oncol Haematol, 1/1/2010
• AXL (AXL receptor tyrosine kinase)  
  Migdall J and DK Graham, Atlas Genet Cytogenet Oncol Haematol, 1/1/2010
• Targeting pediatric acute lymphoblastic leukemia: novel therapies currently in development  
  Lee Sherick AB, Linger RMA, Keating AK, and DK Graham, Br J Haematol, 1/1/2010
• MERTK (c-mer proto-oncogene tyrosine kinase)  
  Keating AK, Linger RMA, and DK Graham, Atlas Genet Cytogenet Oncol Haematol, 1/1/2009
• TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer  
  Linger RMA, Keating AK, Earp HS, and DK Graham, Adv Cancer Res, 1/1/2008
• Novel therapies for pediatric cancer  
  Macy ME, Sawczyn KK, Garrington T, Graham DK, and L Gore, Curr Oncol Rep, 1/1/2008
• A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation  
  Sather SL, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, and DK Graham, Blood, 1/1/2007
• Varicella zoster virus infections in the pediatric stem cell transplant patient  
  Graham DK and RH Giller, Pediatr Pathol Mol Med, 1/1/2000
• A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells  
  Lai KS, Jin Y, Graham DK, Witthuhn B, Ihle JN, and ET Liu, J Biol Chem, 1/1/1995
• Rodent L1 evolution involves the repeated acquisition of new regulatory sequences  
  Adey NB, Schichman SA, Graham DK, Peterson SN, Edgell MH, and CA Hutchison III, Mol Biol Evol, 1/1/1994
• Join now to see all

Books/Book Chapters

• Current Pediatric Diagnosis and Treatment 
  Chapter: Neoplastic disease 
  Page 885 - 916Maloney K, Greffe , Foreman NK, Porter CC, Graham DK, Sawczyn K, Giller RH, Quinones RR, and AK KeatingEditors: Hay WW, Levin MJ, Sondheimer JM, and RR Deterding.McGraw-Hill, New York, NYEdition 18th,2007
• Current Pediatric Diagnosis and Treatment 
  Chapter: Hematopoietic stem cell transplantation 
  Page 916 - 918Graham DK, Giller RH, and RR QuinonesEditors: Hay WW, Groothuis JR, Hayward AR, and MJ Levin.McGraw-Hill, New York, NYEdition 16th,2003
• Peripheral Blood Stem Cells 
  Chapter: Embryonic stem cells: research and clinical potentials 
  Page 65 - 83Snodgrass HR, Graham DK, Stanford WL, and LL LicatoEditors: Smith DM, Sacher RA, and LC Jefferies.American Association of Blood Banks, Bethesda, MD1993

Abstracts/Posters

• Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia
  DeRyckere D, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia
  Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, and DK Graham, American Society of Hematology 56th Annual Meeting; Blood, San Francisco, CA, 1/1/2014
• UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft ...
  DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, and DK Graham, American Society of Hematology 56th Annual Meeting; Blood, San Francisco, CA, 1/1/2014
• Pre-Clinical Evaluation of Novel FLT3 inhibitors effective in FLT3-ITD AML
  Minson KA*, Lee-Sherick A, DeRyckere D, Wang X, Frye SV, Earp HS, and DK Graham, American Society of Pediatric Hematology/Oncology 27th Annual Meeting, Chicago, IL, 1/1/2014
• UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft ...
  DeRyckere D*, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, and DK Graham, American Society of Hematology 56th Annual Meeting, San Francisco, CA, 1/1/2014
• UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute l...
  Graham DK*, DeRyckere D, Wang X, Hill AA, Zhang w, Frye SV, and Earp HS, 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 1/1/2014
• MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia
  Minson KA*, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, and DK Graham, American Society of Hematology 56th Annual Meeting, San Francisco, CA, 1/1/2014
• Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and BRAF mutant melanoma cell lines
  Teodorovic LS*, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition
  Newton TP*, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples
  Lee-Sherick A, Menachof K, Hill A, Rinella S, DeRyckere D, Liu J, Wang X, Frye S, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer
  Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma
  Earp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer
  Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, and DK Graham, American Association of Cancer Researchers Annual Meeting, San Diego, CA, 1/1/2014
• MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia
  Graham DK, DeRyckere D, Lee-Sherick AB, Winges A, Wang X, Zhang W, Liu J, Frye SV, and HS Earp III, American Association of Cancer Researchers Pediatric Cancer at the Crossroads Conference, San Diego, CA, 1/1/2013
• Bioluminescence imaging for assessment of drug efficacy in human leukemia cell lines - Effects of monoclonal and polyclonal cell populations on intensity and kinetics ...
  Christoph S, Schlegel J, Alvarez-Calderon F, Kim Y-M, Brandao LN, DeRyckere D, and DK Graham, AACR-SNMMI State-of-the-Art Molecular Imaging in Cancer Biology and Therapy Joint Conference, San Diego, CA, 1/1/2013
• Mer receptor tyrosine kinase is a novel therapeutic target in melanoma
  Schlegel J, Sambade M, Sather S, Moschos S, Tan A-C, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan P-F, Hamilton RL, Duncan LM, Miller C..., Annual Meeting of the American Association of Cancer Researchers, Washington DC, 1/1/2013
• Preclinical evaluation of UNC1062, a novel small molecule Mer inhibitor for the treatment of multiple myeloma
  Christoph S, Maag S, DeRyckere D, Graham DK, Frye SV, Earp HS, Liu J, Yang C, Zhang W, Wang X, Beelen D, and AH Elmaagacli, Annual Meeting of the German, Austrian, and Swiss Associations of Hematology and Oncology; Onkologie, Vienna, Austria, 1/1/2013
• Novel small molecule Mer kinase inhibitors for the treatment of cancer
  Wang X, Liu J, Zhang W, Stashko MA, DeRyckere D, Cummings C, Hunter D, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, Graham DK, and Frye SV, Drug Discovery & Therapy World Congress, Boston, MA, 1/1/2013
• Structure-based design and synthesis of novel pyrimidine analogs as Mer kinase inhibitors in the treatment of cancer
  Zhang W, McIver A, Zhang D, Kireev DB, Stashko MA, DeRyckere D, Norris-Drouin JL, Machius M, Miley M, Janzen W, Earp HS, Graham DK, Frye SV, and X Wang, 246th American Chemical Society National Meeting & Exposition, Indianapolis, IN, 1/1/2013
• Structure-based design and synthesis of novel 2,4-diaminopyrimidine analogs as Mer kinase inhibitors in the treatment of cancer
  Zhang W, McIver A, Kireev DB, Stashko MA, DeRyckere D, Norris-Drouin JL, Machius M, Miley M, Janzen W, Earp HS, Graham DK, Frye SV, and Wang X, 246th American Chemical Society National Meeting & Exposition, Indianapolis, IN, 1/1/2013
• Inhibition of MerTK in infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer
  Jacobsen KM, Cook RS, Wofford AM, DeRyckere D, Stanford J, Redente E, Hunter DM, Wang X, Frye SV, Earp HS, and DK Graham, 7th Annual American Association of Cancer Researchers Special Conference on Advances in Breast Cancer Research, San Diego, CA, 1/1/2013
• Inhibition of the Gas6/Mer Pathway with novel compounds recapitulates the antithrombotic phenotype of Gas6 -/- or Mer -/- mice in arterial and venous thrombosis models
  Branchford BR, Law L, Sather S, DeRyckere D, Brodsky G, Earp HS, Wang X, Frye S, Graham DK, and JA DiPaola, XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, Netherlands, 1/1/2013
• Pre-Clinical Therapeutic Trials in Zebrafish with T Cell Cancer
  Batchelor L, Trakhimets A, Verma A, Sweeney N, Davis A, DeRyckere D, Christoph S, Graham DK, Trede N, and JK Frazer, Genetics Society of America 5th Strategic Conference of Zebrafish Investigators, Pacific Grove, CA, 1/1/2013
• Development of a novel small molecule inhibitor of the Mer tyrosine kinase for treatment of acute lymphoblastic leukemia
  DeRyckere D, Wang X, Winges A, Zhang W, Stashko MA, Sather S, Cummings C, Janzen WP, Frye SV, Earp HS, and DK Graham, American Society of Hematology Annual Meeting, New Orleans, LA, 1/1/2013
• UNC16666, a dual Mer and Flt-3 tyrosine kinase small molecule inhibitor in acute myeloid leukemia
  Lee-Sherick AB, Menachof K, Hill AA, Rinella A, Liu J, DeRyckere D, Wang X, Frye SV, Earp HS, and DK Graham, American Society of Hematology Annual Meeting, New Orleans, LA, 1/1/2013
• Join now to see all

Lectures

• Targeted inhibition of MerTK as novel cancer therapy 
  Madison, WI - 1/18/2015
• Transitioning MerTK Inhibitors Into the Clinic as Novel Cancer Therapy 
  1/15/2015
• Development of dual Mer/FLT3 inhibitors 
  Boulder, CO - 1/12/2015
• The TAM Family: Phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer 
  National Harbor, MD - 1/6/2015
• Aflac Clinical Trials 
  Atlanta, GA - 1/4/2015
• Development of novel small MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia 
  Paris, France - 1/3/2015
• Genomics and personalized medicine in childhood cancer 
  Montevideo, Uruguay - 1/26/2014
• TAM receptors as cancer therapeutic targets 
  Newark, NJ - 1/24/2014
• Transitioning Mer inhibitors into the clinic 
  Atlanta, GA - 1/15/2014
• Development of novel Mer kinase inhibitors as cancer therapeutics 
  Oklahoma City, OK - 1/14/2014
• Mer RTK inhibitors as clinic therapeutics 
  Boulder, CO - 1/25/2013
• MerTK is a therapeutic target in acute leukemia 
  Raleigh, NC - 1/24/2013
• Mer and Axl inhibitors in non-small cell lung cancer 
  Santa Monica, CA - 1/22/2013
• Efficacy of first in class Mer TKIs in the treatment of leukemia 
  Snow Mountain Ranch, Granby, CO - 1/21/2013
• New strategies for cancer therapy 
  Aurora, CO - 1/21/2013
• New Targeted Cancer Drugs for Pediatric Leukemia 
  New York City, NY - 1/20/2013
• Mer tyrosine kinase is a novel cancer target in pediatric leukemia 
  Miami, FL - 1/13/2013
• Translating guidelines and clinical trial data to improved ALL management and outcomes 
  St. Petersburg, FL, 2013; Hershey, PA, 2013; Durham, NC, 2013 - 1/8/2013
• Mer/Axl Inhibitors 
  Aurora, CO - 1/29/2012
• Mentorship: obligations and expectations 
  Aurora, CO - 1/25/2012
• Mer and Axl are biologic targets in non-small cell lung cancer 
  Santa Monica, CA - 1/24/2012
• Biologically targeted cancer therapy 
  Aurora, CO - 1/16/2012
• Targeting Mer and Axl as novel therapy for melanoma and non-small cell lung cancer 
  Aurora, CO - 1/11/2012
• Novel biologically targeted therapy against the Mer receptor tyrosine kinase in the treatment of pediatric ALL 
  New York, NY - 1/5/2012
• The Mer receptor tyrosine kinase as a novel therapeutic target for ALL 
  University of Toronto, Toronto, Canada - 1/27/2011
• Join now to see all

Other

• The MERTK signaling pathway in cancer 
  Hill AA, Carrico JA, DeRyckere D, and DK Graham, eLS. John Wiley & Sons, Ltd
  1/1/2015